Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution
2024年5月1日 - 9:00PM
ビジネスワイヤ(英語)
Latest addition to the NovoCyte family celebrates a decade of
flow cytometry excellence
Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte
Opteon Spectral Flow Cytometer, propelling flow cytometry into a
new era of and accessibility. This cutting-edge system sets a gold
standard for acquiring, analyzing, and reporting flow data across
diverse domains—from basic research to drug discovery and therapy
development.
The NovoCyte Opteon represents a significant leap forward in
flow cytometry technology, with configurations ranging from three
to five lasers and support for up to 73 high-quality detectors. It
meets researchers’ needs for sophisticated, large-panel flow
cytometry assays while maintaining the easy-to-use features of the
NovoCyte portfolio.
Researchers can now explore cellular mysteries with unparalleled
precision, simultaneously analyzing over 40 markers, providing
great flexibility in flow panel design.
“2024 marks the 10th anniversary of the introduction of NovoCyte
flow cytometry platform. Over the years, the technology-advancing
and capability-enhancing NovoCyte Quanteon, Advanteon, and Penteon
were added into NovoCyte portfolio, helping scientists to advance
their cell analysis research,” stated Xiaobo Wang, vice president
and general manager of Agilent’s Cell Function and Phenotyping
Business.
“The addition of the new NovoCyte Opteon couples the inherent
power of spectral flow cytometry with a highly intuitive analytical
software package which streamlines workflow for high-dimensional,
multi-parametric flow cytometry assays while being exceptionally
easy to use, maintain and automate,” Wang added.
Flow cytometry is a crucial technology employed globally,
spanning academic centers, biotech firms, and pharmaceutical
companies. The NovoCyte Opteon assumes a pivotal role, empowering
researchers with advanced spectral capabilities, user-friendly
design, and customizable features to align with specific research
requirements. Advanced engineering with proprietary technology
ensures optimized light collection and electronic signal
collection, real-time monitoring, and consistent, reliable data
acquisition.
Agilent will officially unveil the NovoCyte Opteon at the CYTO
2024 Conference in Edinburgh, Scotland, happening May 4 – 8,
2024.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in
analytical and clinical laboratory technologies, delivering
insights and innovation that help our customers bring great science
to life. Agilent’s full range of solutions includes instruments,
software, services, and expertise that provide trusted answers to
our customers' most challenging questions. The company generated
revenue of $6.83 billion in fiscal 2023 and employs approximately
18,000 people worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and
Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501954210/en/
Catherine Kaye Agilent Technologies +447775410632
catherine.kaye@agilent.com
Agilent Technologies (NYSE:A)
過去 株価チャート
から 5 2024 まで 6 2024
Agilent Technologies (NYSE:A)
過去 株価チャート
から 6 2023 まで 6 2024